Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Public ClinicalTrials.gov record NCT02114203. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Study identification
- NCT ID
- NCT02114203
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- PDE9i Drug
- placebo for PDE9i Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Aug 31, 2016
- Completion
- Aug 31, 2016
- Last update posted
- Dec 13, 2017
2014 – 2016
United States locations
- U.S. sites
- 12
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Illinois Hospital and Health Sciences System | Chicago | Illinois | 60612-5836 | — |
| University of Illinois at Chicago Clinical Research Center | Chicago | Illinois | 60612 | — |
| University of Illinois Hospital and Health Sciences System | Chicago | Illinois | 60612 | — |
| Boston Medical Center E7E | Boston | Massachusetts | 02118 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Boston University Medical Center | Boston | Massachusetts | 02118 | — |
| Interfaith Medical Center | Brooklyn | New York | 11213 | — |
| Interfaith Medical Center | Brooklyn | New York | 11238 | — |
| UNC Hospitals' Investigational Drug Service Pharmacy | Chapel Hill | North Carolina | 27514 | — |
| UNC School of Medicine Clinical and Translational Research Center | Chapel Hill | North Carolina | 27599 | — |
| Investigational Drug Services | Richmond | Virginia | 23298 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02114203, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 13, 2017 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02114203 live on ClinicalTrials.gov.